OM
PVLA

Opaleye Management’s Palvella Therapeutics PVLA Stock Holding History

Opaleye Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-172,357
Closed -$4.82M – 50
2025
Q1 		$4.82M Buy
+172,357
New +$3.32M 1.07% 19
2020
Q4 		– Sell
-1,813
Closed -$300K – 66
2020
Q3 		$300K Buy
+1,813
New +$413K 0.06% 52

Other funds holding PVLA

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management's PVLA Position: Q2 2025 in Review

Opaleye Management sold out of Palvella Therapeutics (PVLA) in Q2 2025, closing a stake of 172,357 shares — an estimated $4.82M sold.

Opaleye Management first reported a position in PVLA in Q3 2020 and held it in 2 quarters. The position peaked at $4.82M in Q1 2025. 67 funds tracked by Wall St. Rank hold PVLA as of Q2 2025.

  • Opaleye Management reported no remaining Palvella Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Opaleye Management sold 172,357 Palvella Therapeutics shares in Q2 2025, an estimated $4.82M.
  • Opaleye Management first reported a position in Palvella Therapeutics in Q3 2020 and held it in 2 quarters.
  • Opaleye Management's Palvella Therapeutics position peaked at $4.82M in Q1 2025.
  • 67 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2025.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.